anti-CD19 CAR-T cells

Phase 2Cell therapy

TThe Children's Hospital of Zhejiang University School of Medicine

anti-CD19 CAR-T cells is one of 229 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

228

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Acute Lymphoblastic LeukemiaRecruiting

Refractory Non-Hodgkin LymphomaRecruiting

Rheumatoid Arthritis (RA)Not yet recruiting

Relapsed/refractoryRecruiting

LymphomaRecruiting

Autoimmune DiseaseNot yet recruiting

CAR T Cell TherapyRecruiting

ChidamideRecruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Recruiting

Refractory Non-Hodgkin LymphomaPhase 1

Recruiting

Rheumatoid Arthritis (RA)Phase 1

Not yet recruiting

Relapsed/refractoryPhase 1

Recruiting

LymphomaPhase 2

Recruiting

Autoimmune DiseasePhase 2

Not yet recruiting

CAR T Cell TherapyPhase 1

Recruiting

ChidamidePhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

anti-CD19 CAR-T cells

TThe Children's Hospital of Zhejiang University School of Medicine

Phase 2

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Refractory Non-Hodgkin Lymphoma

NCT04545762

Phase 2Recruiting

Lymphoma

NCT05648019

Phase 1Active, not recruiting

Systemic Lupus Erythematosus

NCT06222853

Q2 2027

Phase 1Not yet recruiting

Autoimmune Disease

NCT06420154

Q3 2027

Recruiting

Refractory

NCT06508346

Q1 2028

Phase 1Recruiting

CAR T Cell Therapy

NCT06842589

Clinical

Trials by Indication[1]

B-cell acute lymphoblastic leukemia2 trials

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

Unknown status·YYan'an Affiliated Hospital of Kunming Medical University·Phase 1·NCT04289220·10 enrolled

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

Unknown status·YYan'an Affiliated Hospital of Kunming Medical University·Phase 1·NCT03854994·10 enrolled

Systemic Lupus Erythematosus2 trials

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Active, not recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06222853·22 enrolled

A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)

Unknown status·SShanghai GeneChem Co., Ltd.·Phase 1·NCT03030976·5 enrolled

Autoimmune Disease2 trials

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 1·NCT06420154·9 enrolled

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

Not yet recruiting·PPeking University Third Hospital·Phase 1/2·NCT06821659·9 enrolled

Acute Lymphoblastic Leukemia2 trials

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Completed·VVinmec Research Institute of Stem Cell and Gene Technology·Phase 1·NCT06027957·18 enrolled

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

Recruiting·UUniversity of Utah·Phase 1·NCT06227026·10 enrolled

CAR T Cell Therapy1 trial

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06842589·18 enrolled

8 more indications

Relapsed/Refractory1 trial

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

Recruiting·SShanghai Tongji Hospital, Tongji University School of Medicine·Phase 1·NCT06375161·12 enrolled

Chidamide1 trial

Chidamide Bridging for CAR-T Therapy

Recruiting·—·Phase 1/2·NCT05370547·120 enrolled

Lymphoma1 trial

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Recruiting·KKK Women's and Children's Hospital·Phase 2·NCT05648019·40 enrolled

Leukemia1 trial

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

Unknown status·SShanghai GeneChem Co., Ltd.·Phase 1/2·NCT02672501·30 enrolled

Not yet recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT07544225·6 enrolled

Refractory Non-Hodgkin Lymphoma1 trial

A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting·CC. Babis Andreadis·Phase 1·NCT04545762·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for anti-CD19 CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-CD19 CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-CD19 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Children's Hospital of Zhejiang University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: TThe Children's Hospital of Zhejiang University School of Medicine

anti-CD19 CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q1 2028

Trials by Indication[1]

B-cell acute lymphoblastic leukemia2 trials

Systemic Lupus Erythematosus2 trials

Autoimmune Disease2 trials

Acute Lymphoblastic Leukemia2 trials

CAR T Cell Therapy1 trial

Relapsed/Refractory1 trial

Chidamide1 trial

Lymphoma1 trial

Leukemia1 trial

Refractory1 trial

Systemic Sclerosis (SSc)1 trial

Rheumatoid Arthritis (RA)1 trial

Refractory Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News